Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments: A multicenter, prospective 1-year study

European Journal of Health Economics

Volumn 5, Issue 1, 2004, Pages 22-27

  Garattini, Livio ^a   Castelnuovo, Emanuela ^a   Lanzetta, Paolo ^b   Viscarra, Cecilia ^a   Ricci, Elena ^a   Parazzini, Fabio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Udine Hospital   (Italy)

Author keywords

Aged macular degeneration; Italy; Medical costs; Resource utilization

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUSEN; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; META ANALYSIS; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROGNOSIS; REIMBURSEMENT; RESOURCE MANAGEMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGED; FEMALE; HEALTH CARE COSTS; HOSPITAL DEPARTMENTS; HUMANS; ITALY; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES;

EID: 1542314371     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0198-x     Document Type: Article

References (22)

1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE et al (2001) Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108:697-704
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117:1329-1345
3. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198-207
4. Macular Photocoagulation Study Group (1993) Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 111:1200-1209
5. Macular Photocoagulation Study Group (1991) Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109:1232-1241
6. Fine SL, Berger JW, Maguire MG, Ho AC (2000) Age-related macular degeneration. N Engl J Med 342:483-492
7. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS et al (1977) The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 106:17-32
8. Hyman L (1992) Epidemiology of AMD. In: Hampton GR, Nelson PT (eds.) Age related macular degeneration: principles and practice. Raven: New York, pp. 1-35
9. Pizzarello LD (1987) The dimensions of the problem of eye disease among the elderly. Ophthalmology 94:1191-1195
10. Scott IU, Smiddy WE, Schiffman J, Feuer WJ, Pappas CJ (1999) Quality of life of low-vision patients and the impact of low-vision services. Am J Ophthalmol 128:54-62
11. Klein R, Klein BE, Jensen SC, Meuer SM (1997) The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 104:7-21
12. Macular Photocoagulation Study Group (1997) Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 115:741-747
13. Ferris FL, III, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640-1642
14. Alexander MF, Maguire MG, Lietman TM, Snyder JR, Elman MJ, Fine SL (1988) Assessment of visual function in patients with age-related macular degeneration and low visual acuity. Arch Ophthalmol 106:1543-1547
15. Davis C, Lovie-Kitchin JE, Thomson BJ (1995) Psychological adjustment to age-related macular degeneration. J Vis Impair Blind 1:16-27
16. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI (1998) The psychosocial impact of macular degeneration. Arch Ophthalmol 116;514-520
17. Brown GC, Sharma S, Brown MM, Kistler J (2000) Utility values and age-related macular degeneration. Arch Ophthalmol 118:47-51
18. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D et al (2000) Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 108:1893-1901
19. Bonastre J, Le Pen C, Anderson P, Ganz A, Berto P, Berdeaux G (2002) The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Health Econ Prev Care 3:94-102
20. Denti C, Garattini L, Lanzetta P, Parazzini F, Ricci E, a nome del Gruppo di Studio Progetto CARMA (2002) Costi della Degenerazione Maculare legata all'eta in Italia. L'analisi retrospettiva dello Studio CARMA. Pharmacoeconomics 4:57-63
21. Anonymous (1997) Tariffe delle prestazioni di assistenza ospedaliera erogate in regime di ricovero ordinario e diurno. Allegato 1
22. Kruskal WH, Wallis WA (1952) Use of ranks in one criterion variance analysis. Am Stat Assoc 47:583-621